Cardiac resynchronization therapy (CRT) has proved efficacious in New York Heart Association (NYHA) class III/IV heart failure (HF). This key echocardiographic study assessed the impact of CRT on structural and functional reverse remodeling in patients with NYHA class I/II HF. The REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) trial was a large, prospective, double-blind, controlled trial of CRT in patients with NYHA class I/II HF, a QRS Ն120 ms, left ventricular (LV) end-diastolic dimension Ն55 mm, and LV ejection fraction Յ40% who were randomly assigned to active therapy (CRT-on; nϭ419) or control (CRT-off; nϭ191). Doppler echocardiograms were recorded at baseline, before hospital discharge, and at 6 and 12 months. The present study showed that CRT in patients with NYHA class I/II HF who were already receiving optimal therapy with a ␤-blocker (95%), angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker (97%) resulted in LV reverse remodeling with favorable changes in LV volume, shape, and ejection fraction similar to those that occurred in patients in NYHA class III/IV; however, there were no accompanying changes in LV diastolic function, LV mass, or severity of mitral regurgitation. There was 3-fold greater LV reverse remodeling in patients with a nonischemic origin of HF than in those with an ischemic origin. Our findings have potentially important clinical implications in that CRT may delay or interrupt the natural disease progression of HF in these patients. This and ongoing studies may define an important therapeutic role for CRT in patients with NYHA class I/II, as well as class III/IV HF, especially those cases with a nonischemic cause.
need to treat myocardial siderosis and in particular show that cardiac T2* is a significantly better predictor of cardiac events than the established measures of liver iron and serum ferritin. T2* cardiovascular magnetic resonance has significant potential to lead to the eradication of heart failure-related death in transfusion-dependent anemias when it is available and effective cardiac chelation can be instituted and maintained.
Conclusions: Cardiac T2* magnetic resonance identifies patients at high risk of heart failure and arrhythmia from myocardial siderosis in thalassemia major and is superior to serum ferritin and liver iron. Using cardiac T2* for the early identification and treatment of patients at risk is a logical means of reducing the high burden of cardiac mortality in myocardial siderosis. 3 
Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial
Summary: The presence of moderate saphenous vein graft (SVG) lesions is a major predictor of cardiac events late after coronary artery bypass grafting. We designed a pilot study to test the hypothesis of sealing moderate nonsignificant SVG lesions with paclitaxel-eluting stents (PES) to prevent atherosclerosis progression at the level of the moderate SVG lesion while not inducing any deleterious effect on the atherosclerotic process of the nonstented SVG segments. Patients with at least 1 moderate SVG lesion (30% to 60% diameter stenosis) were randomized either to stenting the moderate SVG lesion with a PES (nϭ30, PES group) or to medical treatment alone (nϭ27, medical treatment group). Patients had an angiographic and intravascular ultrasound evaluation of the SVG at baseline and at 12-month follow-up. Mean time from coronary artery bypass grafting was 12Ϯ6 years, and mean low-density lipoprotein cholesterol level was 73Ϯ31 mg/dL. Significant disease progression occurred in the medical treatment group at the level of the moderate SVG lesion as evaluated by angiography and intravascular ultrasound (PϽ0.01 versus baseline; PϽ0.01 versus PES group), leading to a severe flow-limiting lesion or SVG occlusion in up to 22% of the patients compared with none in the PES group (Pϭ0.014). There were no cases of restenosis or stent thrombosis, and no significant atherosclerosis progression occurred at the nonstented SVG segments. At 12-month follow-up, the cumulative incidence of major adverse cardiac events related to the target SVG was 19% in the medical treatment group versus 3% in the PES group (Pϭ0.091). In conclusion, old and moderately diseased SVGs presented a significant and very rapid (within 12 months) disease progression at the sites exhibiting moderate lesions despite optimal control of lowdensity lipoprotein cholesterol levels, and sealing such moderate lesions with PES prevented this process without inducing any deleterious effect on the atherosclerotic disease of nonstented SVG segments. This pilot study provides early evidence that plaque sealing as a new strategy for the treatment of a challenging subset of patients after coronary artery bypass grafting should be explored further.
Conclusions: Stenting moderate nonsignificant lesions in old SVGs with PES was associated with a lower rate of SVG disease progression and a trend toward a lower incidence of major adverse cardiac events at 1-year follow-up compared with medical treatment alone, despite very low low-density lipoprotein cholesterol values. This pilot study supports further investigation into the role of plaque sealing in SVGs. 4 
Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population
Summary: Faster heart rate (HR) has been associated with all-cause mortality, sudden death, and other adverse outcomes in the general population and in patients with heart disease. The relationship between intrinsic (unpaced) HR, continuously measured by an implanted device, and clinical outcomes was assessed in a large implantable cardioverter-defibrillator population. In these subjects, higher HR was associated with greater risk of death or heart failure hospitalization, with those patients exhibiting a mean HR Ͼ90 bpm experiencing almost a 4-fold difference in events compared with those patients with mean HR Ͻ75 bpm. For patients with implantable cardioverter-defibrillators, HR data can predict outcomes in patients with implantable cardioverter-defibrillators. Beta-Blockers appear to reduce events in a direct relationship to HR. Access to HR trends in patients with implantable cardioverter-defibrillators may assist clinical decision making. HR remains an underutilized, but easily determined, and important clinical predictor in this population.
Conclusion:
In this Implantable Cardioverter-Defibrillator population, the mean intrinsic HR was strongly associated with outcomes. 5
Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Summary: Individuals with diabetes mellitus have an increased risk of cardiovascular disease and exhibit platelet hyperreactivity, increasing their resistance to antithrombotic therapies such as aspirin and clopidogrel. As a consequence, more potent antiplatelet therapeutic strategies are increasingly being used to reduce thrombotic complications in diabetes mellitus; however, these approaches have minimal impact on atherosclerotic lesions themselves, leading to persistent plaque instability. The studies presented here demonstrate the effectiveness of a single infusion of reconstituted high-density lipoprotein (HDL) in attenuating the reactivity of platelets from individuals with diabetes mellitus. Furthermore, these studies suggest that platelet hyperreactivity associated with cholesterol accumulation in platelet membranes can be reversed by reconstituted HDL through cholesterol depletion and disruption of lipid rafts. The greater platelet inhibitory properties of reconstituted HDL compared with native HDL suggest that agents that increase pre-␤-HDL particles would have the greatest efficacy with respect to reducing platelet reactivity. Investigations to determine whether reconstituted HDL infusions or long-term HDL-raising agents confer additional benefits to current antithrombotic agents without adversely affecting hemostasis are required. The present findings add a new dimension to the known antiatherosclerotic actions of reconstituted HDL to provide a rationale for HDL-raising therapies as novel antithrombotic agents.
Conclusion: These findings suggest that rHDL therapy is highly effective at inhibiting the heightened reactivity of diabetic platelets, partly through reducing the cholesterol content of platelet membranes. These properties, combined with the known short-term beneficial effects of rHDL on atherosclerotic lesions, suggest that rHDL infusions may be an effective approach to reduce atherothrombotic complications in diabetic individuals. 6 implantable cardioverter-defibrillator therapy. Over a median follow-up of 45.5 months, 666 deaths were reviewed by an Events Committee and categorized as sudden death presumed to be ventricular tachyarrhythmic, heart failure related, bradyarrhythmic, nonarrhythmic non-heart failure related, or noncardiac. Implantable cardioverter-defibrillator therapy reduced cardiac and ventricular tachyarrhythmic mortality and had no impact on mortality resulting from heart failure or noncardiac causes compared with placebo. The cardiac and ventricular tachyarrhythmic mortality reductions were evident in subjects with New York Heart Association class II but not in subjects with class III heart failure. The reduction in ventricular tachyarrhythmic mortality with implantable cardioverterdefibrillator therapy was similar in subjects with ischemic and nonischemic disease. Amiodarone compared with placebo had no significant effect on any mode of death, although there was an increase in noncardiac mortality in those with New York Heart Association class III heart failure who were receiving amiodarone. Implantable cardioverter-defibrillator therapy has a beneficial effect on reducing sudden death presumed to be due to ventricular tachyarrhythmias without an effect on heart failure mortality.
Conclusions: Implantable Cardioverter-Defibrillator therapy reduced cardiac mortality and sudden death presumed to be ventricular tachyarrhythmic in SCD-HeFT and had no effect on heart failure mortality. Amiodarone had no effect on all-cause mortality or its cause-specific components, except an increase in noncardiac mortality in class III patients. 7
Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis
Summary: There is evidence from retrospective analyses and a prospective trial that a high-sensitivity C reactive protein concentration Ն2.0 mg/L identifies patients who benefit from statin treatment independently of low-density lipoprotein cholesterol reduction. To determine whether similar observations are present in patients with ischemic systolic heart failure, we carried out a retrospective analysis of a large statin trial. Although this trial showed no benefit overall of rosuvastatin on the primary end point or all-cause mortality, the present analysis showed that statin treatment was associated with better outcomes than placebo treatment in patients with a highsensitivity C reactive protein Ն2.0 mg/L than in those with a high-sensitivity C reactive protein Ͻ2.0 mg/L, eg, a hazard ratio for death in the former of 0.89 (95% confidence interval, 0.79 -1.00) and in the latter of 1.17 (95% confidence interval, 0.95-1.43; P for interactionϭ0.026). The possibility that statins might be beneficial in heart failure patients with a high-sensitivity C reactive protein Ն2.0 mg/L needs to be tested prospectively.
Conclusion:
In this retrospective hypothesis-generating study, we found a significant interaction between hs-CRP and the effect of rosuvastatin for most end points whereby rosuvastatin treatment was associated with better outcomes in patients with hs-CRP Ն2.0 mg/L. 8 
Effect of Increased Exercise in School Children on Physical Fitness and Endothelial Progenitor Cells: A Prospective Randomized Trial
Summary: Childhood obesity is the result of a long-lasting imbalance between energy intake and energy expenditure. The decline of physical activity over the last decades is thought to be one of the main risk factors for the development of overweight and obesity and its comorbidities. Therefore, intervention strategies to treat and prevent childhood obesity are necessary. Physical exercise is one of the cornerstones of obesity prevention, and its preventive value has been proven over the last decades. An attractive setting to start and implement such an exercise program is in school, which is indepen-dent of environmental and parental influences. The aim of this prospective randomized trial was to compare sixth-grade students with daily school exercise lessons with a control group with 2 exercise lessons per week with respect to physical fitness, motor skills, body composition, and circulating endothelial progenitor cells as a surrogate parameter for cardiovascular risk/function and tissue repair capabilities. The central message emerging from this study is that some of the harmful trends associated with childhood obesity and sedentary behavior may be reversed by increasing the level of physical activity. In addition, daily exercise leads to an increase of circulating endothelial progenitor cells without improvement of their migratory function. Furthermore, the results demonstrate that implementation of daily exercise lessons into the school curriculum is feasible, well tolerated, and accepted.
Conclusions: Regular physical activity by means of daily school exercise lessons has a significant positive effect on physical fitness (Vo 2 max). Furthermore, the number of circulating progenitor cells can be increased, and there is a positive trend in body mass index-standard deviation score reduction and motor ability improvement. Therefore, we conclude that primary prevention by means of increasing physical activity should start in childhood. 9
Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device
Summary: The HeartMate II left ventricular assist device (LVAD) is a small continuous-flow device that has been shown to provide effective hemodynamic support and improve quality of life in patients being bridged to cardiac transplantation. However, because of the continuous flow of blood with this device, these patients often have no palpable pulse and a very low pulse pressure, and the subsequent effects of continuous flow on end-organ function are unclear. In patients who underwent placement of the HeartMate II as a bridge to transplantation and who were followed up for 6 months of support with the left ventricular assist device, we demonstrated that both hepatic and renal function in patients with abnormal baseline function improved to normal levels by month 1 to 2 and that they remained normal. Additionally, in patients with normal baseline function, we found that renal and hepatic function remained normal during continuous-flow support. In summary, despite low pulsatility, the HeartMate II continuous-flow left ventricular assist device improved both hepatic and renal function in advanced heart failure patients awaiting transplantation.
Conclusions:
The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period. 10
Persistent Diastolic Dysfunction Late After Valve Replacement in Severe Aortic Regurgitation
Summary: Patients with severe aortic regurgitation show eccentric left ventricular hypertrophy and structural changes of the myocardium. Reversibility of functional and structural changes after successful valve replacement may be limited. Persistent diastolic dysfunction was observed in the present study late after aortic valve replacement. This finding is explained by incomplete regression of the extracellular matrix 7 years after valve replacement. Interstitial fibrosis remains unchanged compared with the preoperative situation but was increased early after operation as a result of the reduction in left ventricular muscle mass. Regression of left ventricular hypertrophy was 38% after 2 years and 55% after 7 years of valve replacement. Myocardial muscle fibers decreased slightly but remained hypertrophied even late after operation. Interstitial fibrosis was found to be positively correlated to myocardial stiffness and inversely correlated 
Glycemic Control and Cardiovascular Events in Diabetic Hemodialysis Patients
Summary: Patients on maintenance dialysis treatment experience an excess mortality, which is highest among diabetic patients. Cardiac disease represents the leading cause of death, particularly sudden cardiac death. Evidence suggests that poor glycemic control may affect the arrhythmogenesis of patients with kidney failure because it affects the development of comorbidities, electrolyte balance, function of potassium and calcium channels, and sympathetic activity. In the present study of 1255 hemodialysis patients with type 2 diabetes mellitus, poor glycemic control as represented by elevated levels of glycohemoglobin A 1c (HbA 1c ) was associated with an increased risk of sudden cardiac death. Patients with an HbA 1c Ͼ8% had a 2-fold higher risk of sudden death compared with those with an HbA 1c Յ6% independently of other known risk factors. Although myocardial infarction was not affected, the risks of the combined primary end point and mortality significantly increased at higher levels of HbA 1c and were explained mainly by the impact of glycemic control on sudden cardiac death. By pointing out the importance of distinguishing the pathophysiologically different causes of death, the present study offers new perspectives for future research on glucose control in populations with a high incidence of sudden death. Importantly, these results may suggest novel therapeutic strategies in diabetic hemodialysis patients, in whom sudden cardiac death accounts for a quarter of all deaths. Whether tight glucose control decreases the risk of sudden death without causing side effects remains to be studied.
Conclusions:
Poor glycemic control was strongly associated with sudden cardiac death in diabetic hemodialysis patients, which accounted for increased cardiovascular events and mortality. In contrast, myocardial infarction was not affected. Whether interventions achieving tight glycemic control decrease sudden death requires further evaluation. 12 to 53% of deaths were cardiovascular and only 32% to 35% of the population entered had a prior history of known coronary artery disease. The BARI 2D trial enrolled 2368 patients with stable ischemic heart disease assigned before randomization to percutaneous coronary intervention or coronary artery bypass grafting strata, and we found similar 5-year all-cause and cardiac mortality rates with insulin sensitization versus insulin provision therapy and with a strategy of prompt initial coronary revascularization plus intensive medical therapy or intensive medical therapy alone with revascularization reserved for clinical indication(s). We did not find any difference in the percutaneous coronary intervention stratum compared with intensive medical therapy in all-cause death, cardiac death, or myocardial infarction. Thus, for many patients with type 2 diabetes mellitus and stable but less severe and extensive coronary artery disease, intensive medical therapy is an excellent first-line strategy and does not require immediate prophylactic percutaneous coronary intervention to prevent cardiac death or myocardial infarction. In contrast, prompt coronary artery bypass grafting with an intensive medical therapy and insulin sensitization strategy is superior to a strategy of "watchful waiting" and intensive medical therapy alone in patients with more severe and extensive coronary artery disease to prevent nonprocedural myocardial infarctions that are associated with an increased cardiac mortality risk.
Randomized Comparison of Strategies for Type B Aortic Dissection: The INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) Trial
Conclusions: In many patients with type 2 diabetes mellitus and stable ischemic coronary disease in whom angina symptoms are controlled, similar to those enrolled in the percutaneous coronary intervention stratum, intensive medical therapy alone should be the first-line strategy. In patients with more extensive coronary disease, similar to those enrolled in the coronary artery bypass grafting stratum, prompt coronary artery bypass grafting, in the absence of contraindications, intensive medical therapy, and an insulin sensitization strategy appears to be a preferred therapeutic strategy to reduce the incidence of myocardial infarction. 14
Economic Outcomes of Treatment Strategies for Type 2 Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial
Summary: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) clinical trial randomized patients with diabetes mellitus and coronary disease to prompt coronary revascularization versus medical therapy, as well as to strategies of glycemia control based on use of either insulin sensitizers or drugs that increase insulin provision. Mortality over 5 years was not significantly different, but major cardiovascular events were reduced by revascularization in the coronary artery bypass grafting stratum. The present study shows that revascularization increases 4-year cost significantly, by roughly $5700 (percutaneous coronary intervention) to $20 300 (coronary artery bypass grafting), whereas insulin sensitization increases costs by $1100. Medical therapy was highly cost-effective compared with prompt revascularization in the percutaneous coronary intervention stratum ($600/life-year added), suggesting that revascularization can be delayed until clinically indicated in patients with less extensive coronary disease. Revascularization may be cost-effective in patients with more extensive disease amenable to coronary artery bypass grafting, but this result was less certain with the limited follow-up available.
Conclusions: Prompt coronary revascularization significantly increases costs among patients with type 2 diabetes mellitus and stable coronary disease. The strategy of medical therapy (with delayed revascularization as needed) appears to be cost-effective compared with the strategy of prompt coronary revascularization among patients identified a priori as suitable for percutaneous coronary intervention. 15
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study
Summary: In the present study, ticagrelor compared with highloading-dose clopidogrel achieved more rapid and greater platelet inhibition in patients with stable coronary artery disease. Greater inhibition was also sustained during the maintenance phase, and the offset of action was faster with ticagrelor therapy than with clopidogrel. These pharmacodynamic effects may explain why ticagrelor treatment was associated with a lower occurrence of the primary end point (myocardial infarction, stroke, or cardiovascular death), similar coronary artery bypass graft-related bleeding, and no overall difference in major bleeding compared with clopidogrel therapy in the PLATO (PLATelet inhibition and patient Outcomes) trial.
Conclusions: Ticagrelor achieved more rapid and greater platelet inhibition than high-loading-dose clopidogrel; this was sustained during the maintenance phase and was faster in offset after drug discontinuation. 16
Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial
Summary: On the basis of analysis of 13 819 patients with an acute coronary syndrome treated with contemporary antithrombotic strategies in the randomized Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, we developed prognostic models for the risk of myocardial infarction (MI) and risk of non-coronary artery bypass grafting major bleeding and examined the manner in which bivalirudin compared with heparin plus a glycoprotein IIb/IIIa inhibitor affected these risks in individual patients. The risk factors for MI and major bleeding differed substantially, with only baseline ST-segment deviation and older age predicting both. In a covariate-adjusted analysis, treatment with bivalirudin alone rather than heparin plus a glycoprotein IIb/IIIa inhibitor was associated with a nonsignificant 8% increase in MI but a significant 50% reduction in major bleeding. Both MI and major bleeding affected subsequent mortality rate, with hazard ratios of 2.7 and 2.9, respectively (both PϽ0.001). Given the individual patient risk profiles and the fact that bivalirudin prevented Ϸ6 major bleeds for each MI that might occur, bivalirudin alone rather than heparin plus a glycoprotein IIb/IIIa inhibitor had an estimated reduction in bleeding risk that was greater than the estimated increase in MI risk for nearly all patients. When one considers each patient's risk profile for MI and non-coronary artery bypass grafting major bleeding and the relative risk of these events with alternative antithrombotic strategies, a selection of the optimal pharmacological regimen for the individual patient can be made that would minimize the occurrence of these adverse events and their impact on subsequent mortality rate.
Conclusions: Consideration of the individual patient risk profile for MI and major bleeding and the relative treatment effects of alternative pharmacotherapies permits personalized decision making to optimize therapy of patients with acute coronary syndrome. 17
Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38
Summary: The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed that for patients with acute coronary syndromes and planned percutaneous coronary intervention, prasugrel was associated with a significantly reduced rate of the composite end point of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke at the expense of an increased risk of TIMI major bleeding not related to coronary artery bypass graft surgery. The extent to which prasugrel should be considered the thienopyridine of choice for acute coronary syndrome patients undergoing percutaneous coronary intervention, however, depends not only on the balance between thrombotic and bleeding events but also on the economic implications, especially in light of the potentially large population of patients who may be candidates for this therapy. This study uses data from TRITON to evaluate the cost-effectiveness of prasugrel versus clopidogrel from the perspective of the US healthcare system. Using current drug prices of $4.62/d for clopidogrel and $5.45/d for prasugrel, we found that treatment with prasugrel versus clopidogrel for a median of 14.7 months was associated with lower costs and life expectancy gains both during the initial 30 days and from 31 days throughout the rest of the trial follow-up period, both overall and for most subgroups studied, including high-risk subgroups of patients with diabetes or ST-segment-elevation myocardial infarction. Results from the comparison of prasugrel with generic clopidogrel, likely to become available in the United States in 2011, at a hypothetical price for clopidogrel of $1/d yielded an overall increase in costs during the trial period of $996 per patient and an associated incremental cost-effectiveness ratio of $9727 per life-year gained, still favorable compared with many other accepted interventions.
Conclusion: Among acute coronary syndrome patients with planned percutaneous coronary intervention, treatment with prasugrel versus clopidogrel for up to 15 months is an economically attractive treatment strategy. 18
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus But Are Improved After Extended-Release Niacin Therapy
Summary: High-density lipoprotein (HDL) has long been considered an antiatherosclerotic lipoprotein. This has been suggested on the basis of the inverse association of plasma HDL levels with coronary disease and the risk of cardiovascular events. Furthermore, HDL has been observed to promote reverse cholesterol transport and to exert endothelial-protective effects; however, these effects were demonstrated in HDL from healthy subjects or in reconstituted HDL. The present study suggests that, in contrast to HDL from healthy subjects, HDL from patients with diabetes mellitus and metabolic syndrome loses important endothelial-protective effects, such as the capacity to stimulate endothelial nitric oxide production or to promote endothelial progenitor cell-mediated endothelial repair. These observations are likely important for the understanding of the vascular effects of HDL-raising therapies, which may be particularly vasoprotective if the "on-treatment" HDL exerts beneficial vascular effects. Notably, extended-release niacin therapy, at present the most effective agent in clinical use for increasing HDL, improved the capacity of HDL from diabetic patients to stimulate endothelial-protective effects.
Conclusions: HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelialprotective effects compared with HDL from healthy subjects. Extended release niacin therapy not only increases HDL plasma levels but markedly improves endothelial-protective functions of HDL in these patients, which is potentially more important. 19
Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
Summary: Prior primary prevention trials of statin therapy that used cholesterol criteria for enrollment have not reported significant decreases in stroke risk with active statin therapy. Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) randomized 17 802 men and women without cardiovascular disease with low-density lipoprotein cholesterol levels Ͻ130 mg/dL and high-sensitivity C-reactive protein levels Ն2.0 mg/L to rosuvastatin 20 mg daily or placebo. Active therapy with rosuvastatin reduced overall stroke rates nearly by half (48%), largely because of a 51% reduction in ischemic stroke without an increase in the risk of hemorrhagic stroke. Aside from a small increase in the risk of physician-diagnosed diabetes in the rosuvastatin arm, adverse events were similar in the 2 treatment arms. An updated meta-analysis of data from JUPITER and data from prior primary prevention statin trials (West of Scotland Coronary Prevention Study, Air Force/Texas Coronary Atherosclerosis Prevention Study, and Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese) revealed a statistically significant 25% reduction in the risk of stroke with active statin therapy in the primary prevention setting. Our data suggest that statin therapy prevents stroke in a primary prevention population with normal levels of low-density lipoprotein cholesterol but elevated levels of the inflammatory biomarker high-sensitivity C-reactive protein.
Conclusion:
Rosuvastatin reduces by more than half the incidence of ischemic stroke among men and women with low levels of lowdensity lipoprotein cholesterol levels who are at risk because of elevated levels of high-sensitivity C-reactive protein. 20
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial
Summary: Smoking cessation is a key component of secondary cardiovascular disease (CVD) prevention because smokers who quit after the diagnosis of CVD have a rapid reduction in their risk of recurrence, disease progression, and cardiovascular mortality. Despite these facts, treating tobacco dependence often has a low priority in cardiology practice. The availability of more effective treatments for smoking cessation provides an opportunity to engage cardiovascular clinicians in treating tobacco use. Varenicline, a partial ␣ 4 ␤ 2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with CVD were untested. In this randomized, double-blind, placebocontrolled trial of 714 smokers with stable CVD, varenicline more than tripled the rate of continuous tobacco abstinence compared with placebo at the end of 12 weeks of treatment (47.0% versus 13.9%; odds ratio, 6.11; 95% confidence interval, 4.18 -8.93). The benefit of varenicline persisted even though many patients resumed smoking after treatment stopped. The rate of continuous tobacco abstinence to 1 year was 19.2% in the varenicline group versus 7.2% in the control subjects (odds ratio, 3.14; 95% confidence interval, 1.93-5.11).
Varenicline was well tolerated in smokers with CVD. It was not associated with increases in blood pressure, heart rate, new cardiovascular events, or cardiovascular or all-cause mortality, although the extent of drug exposure for safety assessment was limited. The rates of psychiatric adverse events, about which concern has been raised in postmarketing surveillance of varenicline, were low and comparable between the varenicline and placebo groups. These data provide a strong evidence base to support the use of varenicline for outpatient smokers with stable CVD.
Conclusions: Varenicline is effective for smoking cessation in smokers with cardiovascular disease. It was well tolerated and did not increase cardiovascular events or mortality; however, trial size and duration limit definitive conclusions about safety. 21
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial
Summary: Aortic stenosis is an active process with many similarities to atherosclerosis. Animal studies and retrospective clinical studies have shown statins to be effective in reducing the progression of aortic stenosis. In a randomized, double-blind, placebo-controlled trial of 269 patients with a median follow-up of 3.5 years, we assessed the effect of rosuvastatin 40 mg daily on the progression of aortic stenosis in asymptomatic patients with mild to moderate aortic stenosis and no indication for lipid-lowering therapy. We showed that intensive lipid lowering with rosuvastatin was no better than placebo in reducing the progression of aortic stenosis. The lack of benefit was observed in predefined subgroups, including younger patients, patients with milder aortic stenosis, patients with bicuspid aortic valve, and patients with little or no aortic valve calcification. 
Combined Atrial and Ventricular Antitachycardia Pacing as a Novel Method of Rhythm Discrimination: The Dynamic Discrimination Download Study
Summary: We describe here the dynamic discrimination pacing algorithm in dual-chamber defibrillators that can terminate arrhythmias or discriminate between 1:1 supraventricular tachycardias and ventricular tachycardias if the arrhythmia persists. This novel algorithm considers the rhythm ventricular in origin if the first sensed event after simultaneous atrial and ventricular antitachycardia pacing is on the ventricular channel and supraventricular in origin otherwise. We tested this algorithm in 62 dual-chamber defibrillator recipients who were followed up for 9.6Ϯ3.3 months. The dynamic discrimination algorithm terminated or correctly classified 1379 of 1381 SVT sequences for an overall specificity of 99.9% (generalized estimating equation adjusted, 99.8%) and 23 of 26 VT for an overall sensitivity of 88.5% (generalized estimating equation adjusted, 82.1%). Testing this new algorithm in larger patient populations is warranted.
Conclusions:
We describe here a new pacing algorithm in dualchamber defibrillators that can terminate arrhythmias or discriminate between 1:1 SVT and VT if the arrhythmia persists. Testing this new algorithm in larger patient populations is warranted. 23
No Major Differences in 30-Day Outcomes in High-Risk Patients Randomized to Off-Pump versus On-Pump Coronary Bypass Surgery: The Best Bypass Surgery Trial
Summary: Observational studies comparing off-pump with on-pump coronary artery bypass grafting (CABG) have indicated that highrisk patients will benefit the most from avoiding cardiopulmonary bypass; however, this has not been assessed previously in a randomized trial. In the Best Bypass Surgery trial (nϭ341), off-pump compared with on-pump CABG in patients with 3-vessel disease and a EuroSCORE Ն5 did not result in a significant difference in the 30-day composite outcome including all-cause mortality, acute myocardial infarction, cardiac arrest with successful resuscitation, low cardiac output syndrome/cardiogenic shock, stroke, and coronary reintervention, nor were any of the individual components of the composite outcome significantly different. Off-pump CABG resulted in fewer grafts to the lateral territory of the left ventricle, although the overall number of grafts did not differ significantly between the 2 groups. The Best Bypass Surgery trial found that both off-pump and on-pump CABG can be performed in high-risk patients with low 30-day mortality and morbidity. Off-pump CABG seems to carry a risk of incomplete revascularization, and this may affect long-term mortality and morbidity.
Conclusions: Both off-and on-pump coronary artery bypass grafting can be performed in high-risk patients with low short-term complications. 24
Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes
Summary: Although preventive drug therapy is a priority after myocardial infarction (MI), less is known about adherence to behavioral recommendations. The aim of this study was to examine the influence of adherence to behavioral recommendations on the risk for repeat MI. The study population included 18 809 patients from 41 countries enrolled in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS) 5 randomized clinical trial. One month after presenting with MI, 28.5% reported nonadherence to diet and exercise recommendations, and about one third of smokers persisted in smoking. In models adjusted for known risk factors and medical treatments, quitting smoking was associated with about half the risk of repeat MI compared with persistent smoking (odds ratio, 0.57; 95% confidence interval, 0.36 -0.89), and diet and exercise adherence was associated with about half the risk of repeat MI compared with nonadherence (odds ratio, 0.52; 95% confidence interval, 0.4 -0.69). Persistent smoking and nonadherence to diet and exercise were associated with a 3.8-fold (95% confidence interval, 2.5-5.9) increased risk of cardiovascular events (MI, stroke, and death) compared with risks in never smokers who modified diet and exercise. These analyses highlight the relatively poor adherence to behavioral advice (diet, exercise, and smoking cessation) after MI and suggest that behavioral modification should be given priority similar to other preventive medications immediately after MI because they are associated with substantial benefits in the prevention of repeat events.
Conclusions: Adherence to behavioral advice (diet, exercise, and smoking cessation) after acute coronary syndrome was associated with a substantially lower risk of recurrent cardiovascular events. These findings suggest that behavioral modification should be given priority similar to other preventive medications immediately after acute coronary syndrome. 25
Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy
Summary: The management of patients with moderate-and highrisk acute coronary syndromes has been dramatically improved with the implementation of an early invasive strategy; the use of stents, thienopyridines, and glycoprotein IIb/IIIa inhibitors; and the direct thrombin inhibitor bivalirudin, resulting in substantially lower ischemic and bleeding complication rates. In most contemporary acute coronary syndrome registries, approximately one third of patients enrolled are treated medically after diagnostic angiography, but a paucity of data are available on the outcomes of these medically treated patients. This article focuses on the clinical and angiographic predictors of outcomes of patients enrolled in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial who were treated medically. In this population, composite ischemia was common, occurring in 9.5% of patients at 1 year. The present study shows that among medically treated acute coronary syndrome patients, the use of bivalirudin, regardless of the addition of glycoprotein IIb/IIIa inhibitors, was associated with significant reductions in bleeding at 30 days compared with those treated with heparin plus glycoprotein IIb/IIIa inhibitors, without increasing the rate of composite ischemic events. In addition, angiographic markers of more extensive and severe coronary artery disease and coronary ectasia were important independent markers of outcome and provided significant added prognostic value to the clinically based Thrombolysis in Myocardial Infarction risk score. These results emphasize the utility of angiographic screening for risk stratification among moderate-and high-risk acute coronary syndrome patients, including those triaged to medical therapy.
Conclusions: Among the ACUITY acute coronary syndrome patients treated medically after angiographic triage, bivalirudin therapy significantly reduced bleeding complications compared with heparin without any negative impact on ischemic outcomes at 1 year. The most powerful predictors of ischemic outcomes were angiographic rather than traditional clinical parameters, supporting the early use of angiographic screening in the moderate-and high-risk but medically treated acute coronary syndrome population. 26
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials
Summary: The use of statins in patients with manifest cardiovascular disease is established, with similar benefits seen in women and men, but statin use for the primary prevention of cardiovascular disease is controversial, particularly for women. We analyzed sex-specific outcomes in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and conducted an updated meta-analysis of statin use for women in primary prevention (20 147 women; Ͼ276 cardiovascular disease events; mean age, 63-69 years). JUPITER was a multicenter randomized trial designed to assess the benefits and risks of statin therapy in apparently healthy individuals selected on the basis of elevated high-sensitivity C-reactive protein, a marker of higher cardiovascular risk, without a concomitant elevation in low-density lipoprotein cholesterol. JUPITER participants included 6801 women Ն60 years of age and 11 001 men Ն50 years of age with high-sensitivity C-reactive protein Ն2 mg/L and low-density lipoprotein cholesterol Ͻ130 mg/dL who were randomized to rosuvastatin 20 mg/d versus placebo. Absolute cardiovascular disease rates for rosuvastatin and placebo in JUPITER were lower for women than for men, but there were similar and significant relative risk reductions in both women (by 46%) and men (by 42%). In women, there was significant reduction in revascularization/unstable angina and nonsignificant reductions in other components of the primary end point. Furthermore, in this updated meta-analysis of statin therapy for primary prevention in women, statin allocation yielded a significant relative risk reduction in cardiovascular disease by one-third, similar to prior results in men and in secondary prevention in women.
Conclusion: JUPITER demonstrated that in primary prevention rosuvastatin reduced cardiovascular disease events in women with a relative risk reduction similar to that in men, a finding supported by meta-analysis of primary prevention statin trials. 27
Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure
Summary: Previous studies have suggested that monitoring of ambulatory hemodynamics may improve outcomes in chronic heart failure. We conducted a prospective, observational, first-in-human study of a physician-directed patient self-management system targeting left atrial pressure (LAP). In this study, patients with reduced or preserved left ventricular ejection fractions and a history of New York Heart Association class III to IV heart failure and acute decompensation were implanted with an investigational LAP monitor, and readings were acquired twice daily. For the first 3 months, patients and clinicians were blinded to these readings, and treatment continued per usual clinical assessment. Thereafter, LAP readings and individualized therapy instructions guided by these pressures were displayed to the patient. Event-free survival without decompensation was 61% at 3 years, and events tended to be more favorable after the first 3 months once therapy was being guided by daily LAP readings. Mean daily LAP fell in the first 3 months during pressure-guided therapy. The frequency of elevated readings (Ͼ25 mm Hg) was reduced significantly during LAP-guided therapy, and there were improvements in New York Heart Association class and left ventricular ejection fraction. Doses of angiotensinconverting enzymes/angiotensin-receptor blockers and ␤-blockers were uptitrated significantly, by 37% and 40%, respectively, whereas there was a trend to lower doses of loop diuretics. These findings suggest that physician-directed patient self-management of LAP has the potential to improve hemodynamics, symptoms, and outcomes in advanced heart failure. Hemodynamic monitoring may guide more optimal dosing with proven neurohormonal antagonist therapies.
Conclusions: Physician-directed patient self-management of left atrial pressure has the potential to improve hemodynamics, symptoms, and outcomes in advanced heart failure. 28
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial
Summary: The thiazolidinedione class of drugs has many favorable metabolic and vascular anatomic effects in people with type 2 diabetes mellitus. Whereas the Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History (APPROACH) trial did not show a clear reduction in coronary atherosclerosis versus glipizide, its results are consistent with other studies of rosiglitazone and pioglitazone that did suggest reduced carotid and coronary atherosclerosis. Moreover, the large randomized outcomes trials of the thiazolidinediones that have been completed to date are consistent with the hypothesis that (1) pioglitazone may reduce cardiovascular outcomes compared with placebo and (2) the effect of rosiglitazone on cardiovascular outcomes is similar to that of metformin and to that of sulfonylureas. With the exception of fluid retention and pulmonary edema, these trial findings support the importance of clearly testing the cardiovascular effects of both of these drugs within 1 trial. The Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) trial is a large placebo-controlled trial of 16 000 participants that is currently assessing the cardiovascular effects of both thiazolidinediones versus placebo when added to current therapy. It will also clearly evaluate whether either of the 2 thiazolidinediones differ with respect to cardiovascular outcomes and will clearly determine whether either or both of these drugs prevents, promotes, or has a neutral effect on serious cardiovascular outcomes.
Conclusions: Rosiglitazone did not significantly decrease the primary end point of progression of coronary atherosclerosis more than glipizide in patients with type 2 diabetes mellitus and coronary atherosclerosis. 29
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study
Summary: The Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies (RESPOND) study is the first to demonstrate that ticagrelor therapy overcomes nonresponsiveness to and high platelet reactivity during clopidogrel therapy. The antiplatelet effect of ticagrelor is essentially uniform and high in both clopidogrel responders and nonresponders. Moreover, platelet inhibition in patients responsive and nonresponsive to clopidogrel is enhanced by switching to ticagrelor therapy. These data suggest that ticagrelor may be an important therapeutic alternative in patients who have experienced thrombotic events during clopidogrel therapy. The extremely low prevalence of high platelet reactivity associated with ticagrelor therapy as defined by cut points associated with ischemic event occurrence with the use of 3 different methods in the RESPOND study provides a mechanism for the clinical benefit demonstrated in the Platelet Inhibition and Patient Outcomes (PLATO) trial. All of these findings support the particular utility of ticagrelor in clinical settings associated with high platelet
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reactivity, such as acute coronary syndromes, percutaneous coronary intervention, and stent thrombosis.
Conclusions: Ticagrelor therapy overcomes nonresponsiveness to clopidogrel, and its antiplatelet effect is the same in responders and nonresponders. Nearly all clopidogrel nonresponders and responders treated with ticagrelor will have platelet reactivity below the cut points associated with ischemic risk. 30
Dietary Intervention to Reverse Carotid Atherosclerosis
Summary: The main findings in this study are as follows: (1) 
Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies
Summary: Treatment of bifurcation coronary lesions generates much debate. The BBC ONE study recruited 500 patients with coronary bifurcation lesions and randomly allocated them to either a simple strategy (main-vessel stenting with or without kissing balloon dilatation/T stenting) or a complex strategy (complete lesion coverage with either crush or culotte stenting plus mandatory kissing balloon dilatation). Clinical follow-up of these 2 groups to 9 months showed an 8% major adverse event rate in the simple group versus a 15% major adverse event rate in the complex group. This difference was largely driven by periprocedural myocardial infarction. The study therefore suggests that the usual strategy for the majority of bifurcation lesions should be the simple provisional strategy and that more complex strategies should be reserved for more complex anatomies, involving perhaps large side branches with significant length ostial side-branch disease.
Conclusions: When coronary bifurcation lesions are treated, a systematic 2-stent technique results in higher rates of in-hospital and 9-month major adverse cardiovascular events. This difference is largely driven by periprocedural myocardial infarction. Procedure duration is longer, and x-ray dose is higher. The provisional technique should remain the preferred strategy in the majority of cases. 32
Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial
Summary: Defining the mode of death in patients with heart failure and a preserved ejection fraction (HFPEF) may help to improve our understanding of the underlying pathophysiology in these patients with heart failure and provide insights into appropriate targets for the development of new therapies. Despite advanced age and the presence of comorbid states in patients with HFPEF, the mode of death was cardiovascular in 60% of the patients. In addition, the most common modes of cardiovascular death in patients with HFPEF were heart failure death and sudden death. These facts have implications both for the development of novel management strategies and for the design of future studies to test these strategies in patients with HFPEF. Management strategies that reduce causes of sudden death (such as reduction of arrhythmias) and prevent progression of heart failure (such as improvement in diastolic function and reduction of diastolic pressures) may be able to decrease cardiovascular death rates in patients with HFPEF. Therefore, new management strategies for patients with HFPEF should focus on treatments that can reduce arrhythmias and improve diastolic function. However, management strategies that target cardiovascular causes of mortality are not likely to affect the 30% of mortalities caused by noncardiovascular modes of death. Therefore, treatment of patients with HFPEF should also target the noncardiovascular comorbid states that are commonly present in these patients.
Conclusions: Sixty percent of the deaths in patients with HFPEF were cardiovascular, with sudden death and heart failure death being the most common. Treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates. 33 
B Vitamins and the Risk of Total Mortality and

Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both
Summary: The prevalence of erectile dysfunction is 20% to 30% in the general population but increases to more than 50% in the cardiovascular high-risk population of the ONTARGET/TRANSCEND trials, who are commonly encountered in clinical practice. Moreover, erectile dysfunction is associated with cardiovascular risk factors owing to the physiology of penile erection, which is crucially dependent on endothelial function and nitric oxide synthesis. The prospective erectile dysfunction substudy of the ONTARGET/TRANSCEND trials shows for the first time that erectile function is a predictor of cardiovascular morbidity and mortality. These results remained after adjustment for possible confounders. Thus, erectile dysfunction represents an early symptom of endothelial dysfunction and atherosclerosis, and patients with erectile dysfunction are at a particularly high cardiovascular risk. The identification of these patients with erectile dysfunction offers the opportunity for early risk-adjusted treatment with the goal of further reducing cardiovascular events.
Conclusions: Erectile dysfunction is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen erectile dysfunction. 35
Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
Summary: M118 is a novel low-molecular-weight heparin that has been rationally designed to capture the desired attributes of both unfractionated heparin and low-molecular-weight heparin: Potent activity against both factor Xa and IIa, predictable pharmacokinetics after both intravenous and subcutaneous administration, ability to be monitored by use of point-of-care coagulation assays, and reversibility with protamine sulfate. We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention. The results of the EMINENCE trial demonstrate that M118 is well tolerated and feasible to use as anticoagulant therapy during percutaneous coronary intervention. It exhibits a dose-dependent increase in the activated clotting time and is noninferior to unfractionated heparin with respect to a broad composite of end points that reflect complications related to percutaneous coronary intervention. In addition to clinical outcomes, angiographic outcomes were excellent and comparable between unfractionated heparin and M118. Although a range of doses of intravenous M118 were comparable to unfractionated heparin at preventing a broad composite of percutaneous coronary intervention-related complications, we conclude that a dose range of 75 to 100 IU/kg appears most promising and should be tested further in a phase 3 trial.
Conclusions: This phase 2 randomized trial demonstrates that M118 is well tolerated and feasible to use as an anticoagulant in patients undergoing elective percutaneous coronary intervention and forms the basis for further investigation of this agent in ischemic heart disease. 36
Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease: Observations From Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36)
Summary: Sex differences in some of the mechanisms of ischemic heart disease exist, and as a result, the presentations and responses to therapy can differ between women and men. Thus, we first conducted a prospectively planned analysis of the clinical, biomarker, angiographic, Seattle Angina Questionnaire, and continuous ECG monitoring data in the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) trial to evaluate the characteristics and contemporary treatment strategies in Ͼ2000 women with unstable ischemic heart disease. The findings suggested that despite having less obstructive epicardial coronary disease detected during angiography, women were more likely than men to report anginal episodes and had more recorded ischemic periods on continuous ECG. Second, recognizing the potential for different responses to pharmacological therapy in women and men, we were interested in evaluating the sex-specific antiischemic properties of ranolazine in the MERLIN-TIMI 36 trial. In prior, smaller studies, sex-based treatment differences have been observed with ranolazine, with a possibly diminished effect in women. However, in MERLIN-TIMI 36, which serves as the largest assessment of ranolazine in women to date, we found that ranolazine may be a particularly efficacious antiischemic agent in women.
Conclusions: Women with a clinical syndrome consistent with unstable ischemic heart disease, despite having less obstructive coronary artery disease, were more likely than men to report anginal episodes and had more recorded ischemic periods on continuous ECG. In this setting, ranolazine may be a particularly useful antiischemic agent in women. 37
Reducing Consumption of Sugar-Sweetened Beverages Is Associated With Reduced Blood Pressure: A Prospective Study Among United States Adults
Summary: Consumption of sugar-sweetened beverages (SSBs) has increased dramatically in the United States. Although high SSB consumption has been linked to excess calorie intake and overweight/obesity, SSBs may have other adverse effects. In a prospective study of 810 US adults with prehypertension and stage I hypertension, we found that reducing SSB consumption was associated with significant reductions in blood pressures (BP). On average, a reduction in SSB intake of 1 serving a day (12 oz/d) was associated with a 1.8-mm Hg reduction in systolic BP and 1.1-mm Hg reduction in diastolic BP over 18 months. A positive association was also found for dietary sugar intake and BP. No association was found for diet beverage consumption or caffeine intake and BP. These findings have important clinical and public health implications. It has been estimated that a 3-mm Hg reduction in systolic BP should reduce stroke mortality by 8% and coronary heart disease mortality by 5%. Such reductions in systolic BP would be anticipated by reducing SSB consumption by an average of 2 servings per day. Currently, the average intake of SSBs is 2.3 servings per day for US adults. Nationwide, 72 million US adults (35%) have hypertension, and another 59 million (29%) have prehypertension. Given the high prevalence of both SSB consumption and hypertension in the United States and throughout much of the world, even small reductions in SSB consumption should have a beneficial public health impact. In conclusion, our data suggest that reducing SSB and sugar consumption may be an important dietary strategy to lower BP.
Conclusions: Reduced consumption of SSB and sugars was significantly associated with reduced BP. Reducing SSB and sugar consumption may be an important dietary strategy to lower BP. 38
Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease: Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial
Summary: Choosing the optimal antiplatelet regimen for a patient requires a thorough understanding of not only the benefits of therapy but the risks as well. This is especially important now that several different antiplatelet agents are available. The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial is the largest and longest study of the risks of dual antiplatelet therapy, and this analysis of CHARISMA data provides insights into the frequency of bleed-
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ing, risk factors for bleeding, and consequences of bleeding. Clinicians will find the data useful when they try to balance the risks and benefits of dual antiplatelet therapy with aspirin and clopidogrel in stable patients with vascular disease or with risk factors for vascular disease, like those enrolled in the CHA-RISMA trial.
Conclusions: In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel. The incremental risk of bleeding was greatest in the first year and similar thereafter. Moderate bleeding was strongly associated with mortality. 39
The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus: Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial
Summary: Antiplatelet agents are widely reported to be effective in preventing the recurrence of cardiovascular events. Clinical guidelines have recommended that individuals with risk factors for coronary heart disease (eg, diabetes mellitus) take aspirin for both primary and secondary prevention. Cilostazol, a phosphodiesterase III inhibitor with antiplatelet, antithrombotic, vasodilatory, and antiproliferative effects, is currently indicated for the treatment of intermittent claudication and/or ischemic signs and symptoms associated with chronic arterial occlusion around the world and secondary prevention of cerebral infarction in Asian countries. However, there was no report comparing the efficacy and usefulness of 2 different antiplatelet drugs, aspirin and cilostazol, in the prevention of occurrence or progression of atherosclerosis in diabetic patients. This is the first study to directly compare the effect of cilostazol and aspirin on the progression of atherosclerosis in diabetic patients. In this international, prospective, randomized, open, blinded end point study involving a total of 329 Asian type 2 diabetic patients suspected of peripheral artery disease, we found that cilostazol treatment (100 -200 mg/d) potently and safely inhibited the progression of carotid intima-media thickness, an established surrogate marker of cardiovascular events, compared with aspirin treatment (81-100 mg/d) during a 2-year observation period. Our findings suggest that cilostazol is a more effective antiatherosclerotic agent than aspirin in patients with type 2 diabetes mellitus. A large-scale prospective trial is needed to establish the usefulness of cilostazol for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Conclusions: Compared with aspirin, cilostazol potently inhibited progression of carotid intima-media thickness, an established surrogate marker of cardiovascular events, in patients with type 2 diabetes mellitus. 40
Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial
Summary: Contemporary consensus treatment guidelines continue to recommend coronary artery bypass grafting (CABG) as the "gold standard" for revascularization of unprotected left main (LM) stenosis but note that percutaneous coronary intervention (PCI) is feasible; for example, the American College of Cardiology/American Heart Association PCI guidelines recently upgraded LM PCI from a class III to class IIb (level B) recommendation. In the absence of a large randomized controlled trial, interventional cardiologists have had difficulty developing objective evidence-based criteria for determining the optimal revascularization strategy for a given patient. Conclusions: Patients with LM disease who had revascularization with PCI had safety and efficacy outcomes comparable to CABG at 1 year; longer follow-up is required to determine whether these 2 revascularization strategies offer comparable medium-term outcomes in this group of complex patients. 41
Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial
Summary: Collateral flow to the infarct artery territory after acute myocardial infarction may be associated with improved clinical outcomes and may also impact the benefit of subsequent recanalization of an occluded infarct-related artery. To clarify the impact of collateral flow on clinical outcomes and its interaction with the impact of percutaneous coronary intervention of an occluded infarct artery, 2173 patients with total occlusion of the infarct artery 3 to 28 days after myocardial infarction from the randomized Occluded Artery Trial were analyzed as a function of angiographic collaterals at baseline angiography. The presence and importance of angiographic collaterals at baseline were generally inversely correlated with the risk of subsequent adverse clinical outcomes and specifically associated with better left ventricular function and lower prevalence of heart failure, but collateral flow was not an independent predictor of clinical outcomes, nor was there any interaction with the results of randomized treatment assignment on clinical outcomes: Late recanalization of the infarct artery in addition to medical therapy showed no benefit compared with medical therapy alone, regardless of the presence or absence of collaterals. Therefore, although collaterals may protect the myocardium against ischemia during an evolving acute myocardial infarction, the presence of collaterals after the acute phase was not an independent predictor of subsequent clinical outcomes once infarction was completed. In addition, clinical decisions in patients with recent myocardial infarction should not be based on the presence or grade of angiographic collaterals.
Conclusions:
In recent myocardial infarction, angiographic collaterals to the occluded infarct artery are correlates but not independent predictors of major clinical outcomes. Late recanalization of the infarct artery in addition to medical therapy shows no benefit compared with medical therapy alone, regardless of the presence or absence of collaterals. Therefore, revascularization decisions in patients with recent myocardial infarction should not be based on the presence or grade of angiographic collaterals. 42
Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Summary: The Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) was designed to assess longitudinal clinical course and disease management in the largest cohort of patients with pulmonary arterial hypertension ever monitored. Pulmonary arterial hypertension remains a morbid disease unless well-timed clinical intervention is implemented. Therefore, factors that determine survival in pulmonary arterial hypertension can significantly drive and focus clinical management. We analyzed data from 2716 patients with pulmonary arterial hypertension to derive a multivariable, weighted risk formula that could be used by the practicing clinician at any time in the course of a patient's disease progression to predict survival. Nineteen independent factors were identified as having an impact on patient survival. A multivariable risk formula comprising all 19 factors provided a more accurate assessment of clinical outcome than each independent variable. These results emphasize the importance of using the full spectrum of clinical data commonly available to the practicing clinician for the assessment of patients with pulmonary arterial hypertension. We believe that the risk stratification provided by this predictive equation will facilitate counseling of patients about their disease and prognosis and will provide a benchmark for prospective evaluation of new therapies.
Conclusions:
We identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation. Use of this tool may allow the individualization and optimization of therapeutic strategies. Serial follow-up and reassessment are warranted. 43
Relationship of Intraoperative Cerebral Oxygen Saturation to Neurodevelopmental Outcome and Brain Magnetic Resonance Imaging at 1 Year of Age in Infants Undergoing Biventricular Repair
Summary: This study explored whether intraoperative cerebral oxygen saturation (rSo 2 ) measured by near-infrared spectroscopy was associated with neurodevelopmental outcomes at age 1 year among infants undergoing biventricular repair without aortic arch reconstruction. Lower Psychomotor Development Index of the Bayley Scales was modestly associated with lower rSo 2 during the 60minute period after cardiopulmonary bypass and at the time points of 10 minutes of cooling, off-cardiopulmonary bypass, and 60 minutes after cardiopulmonary bypass. Lower rSo 2 from postinduction to 60 minutes after cardiopulmonary bypass and for the 60-minute period after cardiopulmonary bypass was associated with hemosiderin foci on qualitative MRI analysis. No relationship could be demonstrated between rSo 2 and the Mental Development Index of the Bayley Scales, neurological examination, or head circumference. The relationship of lower rSo 2 with lower Psychomotor Development Index score and greater risk of hemosiderin on brain MRI, even after adjustment for age Յ30 days or diagnosis group, suggests that periods of intraoperative and early postoperative decreased cerebral oxygen delivery are associated with adverse longer-term neurodevelopmental outcomes.
Conclusions: Perioperative periods of diminished cerebral oxygen delivery, as indicated by rSo 2 , are associated with 1-year Psychomotor Development Index and brain MRI abnormalities among infants undergoing reparative heart surgery. 44
B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood: Evaluation as a Potential Biomarker of Cardiac Ischemia
Summary: The clinical diagnosis of acute coronary syndromes relies heavily on circulating diagnostic biomarkers such as troponin. However, delays in detectable changes in circulating troponin, combined with their absence in ischemia short of infarction, result in clinical uncertainty in a significant number of patients presenting with suspected acute coronary syndromes. Thus, identification of novel biomarkers that may provide early information on acute myocardial infarction and cardiac ischemia is of major importance. We provide here the identification of a novel potential biomarker of acute coronary syndromes, namely a peptide fragment derived from the signal peptide region of B-type natriuretic peptide (BNPsp). BNPsp is present as a distinct peptide in explant human cardiac tissue and is secreted into the circulation in normal health. Furthermore, detectable elevations in BNPsp were observed in ST-elevation myocardial infarction patients significantly earlier than myoglobin, creatine kinase-MB, and troponin. BNPsp thus presents as a novel class of potential biomarker in acute coronary syndromes, and further studies to determine its assay specificity and diagnostic potential in the complete spectrum of acute coronary syndromes are clearly warranted.
Conclusion:
Our results demonstrate for the first time that BNPsp exists as a distinct entity in the human circulation and could serve as a new class of circulating biomarker with the potential to accelerate the clinical diagnosis of cardiac ischemia and myocardial infarction. 45
Efficacy and Safety of Automatic Remote Monitoring for Implantable Cardioverter-Defibrillator Follow-Up: The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) Trial
Summary: Cardiac implantable electronic devices are increasing in prevalence. Postimplantation follow-up is important for monitoring both device function and patient condition. Currently, follow-up care follows guidelines that lack supporting data, leading to inconsistent clinical practice. Conventional in-person evaluation, if performed every 3 to 6 months, generates a huge clinical burden, but its efficacy with regard to patient safety, adherence, incidence of unscheduled encounters, and rate of problem detection remains untested. The absence of monitoring between hospital interrogations permits potentially important clinical data to remain concealed. Remote monitoring technology incorporated into devices holds the promise of resolving these problems. The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) trial in patients with defibrillators confirmed significant limitations of conventional care but, in contrast, affirmed the safety, efficacy, and early warning capability (ie, within 24 hours) of automatic remote monitoring. The outcome measure of hospital use was reduced by almost 50% compared with conventional care. The alert capability and archiving power of this remote management system suit it for system performance monitoring and management of devices placed under advisory notices. The results are important for heart failure patients in whom continuous surveillance with the ability to self-declare parameter deviations may permit early clinical intervention. The trial results have significant implications for the management of patients receiving implantable electronic cardiac devices.
Conclusions: Remote home monitoring is safe and allows more rapid detection of actionable events compared with conventional monitoring in patients with implantable electronic cardiac devices. 46 systolic and diastolic function and for poor growth. Extrapolation of data from the adult literature has led to the empirical use of angiotensin-converting enzyme inhibitor therapy in this population; however, its efficacy has never been studied. The Pediatric Heart Network conducted a multicenter, double-blind, placebo-controlled trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ) or placebo and followed up to 14 months of age. Overall, the majority of the study population had normal ventricular function and no clinical heart failure at 14 months of age, regardless of the treatment group.
Growth was significantly impaired, and there were neurodevelopmental abnormalities noted. The incidence of death or transplantation was 13% and did not differ between treatment groups. Administration of enalapril did not improve somatic growth, ventricular function, or heart failure severity. The results of this randomized trial do not support the routine use of enalapril in this population.
Conclusions: Administration of enalapril to infants with singleventricle physiology in the first year of life did not improve somatic growth, ventricular function, or heart failure severity. The results of this randomized trial do not support the routine use of enalapril in this population. 47
Relationship Between Nonsustained Ventricular Tachycardia After Non-ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death: Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial
Summary: Nonsustained ventricular tachycardia (VT) occurs frequently in patients hospitalized with acute coronary syndromes, although the clinical implications of VT remain uncertain, in particular relative to the absolute risk of sudden cardiac death in patients with shorter episodes of ventricular ectopy and the relationship between the timing of VT after hospital admission and prognosis. In this study of Ͼ6300 patients admitted with non-ST-elevation acute coronary syndrome and enrolled in the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) trial who had 7-day continuous ECG monitoring, we found a Ͼ2-fold increase in the risk of sudden cardiac death in patients with both short (4 -7 beats in length) and longer (Ն8 beats in length) episodes of VT compared with patients with no VT. This relationship was unchanged after adjustment for clinical characteristics, including left ventricular ejection fraction and natriuretic peptides. In contrast, there was no increased risk of sudden cardiac death in patients with ventricular triplets. In regard to timing of VT, we found that only episodes occurring Ͼ48 hours after admission were associated with an increased risk of sudden cardiac death, whereas earlier episodes within 48 hours did not carry the same risk.
In several subgroups (history of heart failure, depressed ventricular function, QTc Ͼ450 milliseconds), the presence of VT was associated with a Ͼ10% incidence of sudden cardiac death at 1 year. The results of our study suggest that the use of extended continuous ECG monitoring beyond 48 hours after admission for non-ST-elevation acute coronary syndrome to detect the presence of even short episodes of VT may potentially identify patients at higher risk for sudden death.
Conclusion: Nonsustained VT is common after admission for non-ST-elevation acute coronary syndrome, and even short episodes of VT lasting 4 to 7 beats are independently associated with the risk of sudden cardiac death over the subsequent year. 48
Short-and Medium-Term Outcomes After Transcatheter Pulmonary Valve Placement in the Expanded Multicenter US Melody Valve Trial
Summary: Data from this updated analysis of the multicenter US trial provide further support for the technical feasibility, safety, and probable clinical benefit of the Melody valve in patients with dysfunctional right ventricular outflow tract conduits or bioprosthetic valves. These short-and medium-term outcomes also highlight the need for better understanding of and additional data on procedural complications, as well as risk factors for stent fracture and device failure. Transcatheter pulmonary valve technology may extend the lifetime of surgically implanted conduits and valves and may favorably shift the risk-benefit balance in favor or earlier reintervention in many patients with chronic pulmonary regurgitation and/or conduit obstruction.
Conclusions:
In this updated report from the multicenter US Melody valve trial, we demonstrated an ongoing high rate of procedural success and encouraging short-term valve function. All reinterventions in this series were for right ventricular outflow tract obstruction, highlighting the importance of patient selection, adequate relief of obstruction, and measures to prevent and manage stent fracture. 49
Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)
Summary: Heart failure (HF) is a chronic progressive disease that results in substantial morbidity, mortality, and expenditure of healthcare resources. Despite compelling scientific evidence and professional society guidelines, beneficial therapies for HF remain underused and inconsistently applied in many care settings. New, more effective approaches to improve the use of guideline-recommended therapies for HF are needed. The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) prospectively tested a multidimensional practicespecific performance improvement intervention on the use of guideline-recommended therapies for HF in outpatient cardiology practices. Performance data were collected in a random sample of HF patients from 167 outpatient cardiology practices at baseline (preintervention), longitudinally following intervention at 12 and 24 months, and in unique patient cohorts at 6 and 18 months. Participants included 34 810 patients with reduced left ventricular ejection fraction and chronic HF or post-myocardial infarction. Interventions included clinical decision support tools, structured improvement strategies, and chart audits with performance feedback. The performance improvement intervention resulted in significant improvements in 5 of 7 quality measures at the 24-month assessment compared to baseline. Improvements in the unique single-point-intime cohorts were smaller. The results of this study suggest a favorable impact of applying performance improvement techniques of clinical decision support, reminder systems, guideline-driven care improvement tools, educational outreach, collaborative support, performance profiling, and feedback in real-world cardiology practices. These findings may also help to establish a model and framework for future performance-improvement programs administered in the outpatient setting.
Conclusions:
The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting, a defined and scalable practice-specific performance improvement intervention, was associated with substantial improvements in the use of guideline-recommended therapies in eligible patients with HF in outpatient cardiology practices. 50 e854 Circulation December 13, 2011
Cardiac Positron Emission Tomography/Computed Tomography Imaging Accurately Detects Anatomically and Functionally Significant Coronary Artery Disease
Summary: Accurate noninvasive assessment of coronary artery disease is a challenging task. In a cohort of 107 patients at intermediate clinical risk, we measured the power of hybrid positron emission tomography and computed tomography coronary angiography against invasive coronary angiography with fractional flow reserve for the detection of obstructive coronary artery disease. Although both computed tomography angiography and positron emission tomography individually were able to rule out significant coronary artery disease (negative predictive value, 97%), both approaches showed only modest positive predictive value. Positron emission tomography perfusion imaging alone could not always separate microvascular dysfunction from epicardial stenoses, whereas computed tomography angiography was limited in defining the physiological significance of anatomic stenosis. Hybrid positron emission tomography/computed tomography significantly improved this accuracy to 98%. This was achieved with a rapid 30-minute imaging protocol with a reasonable radiation dose (Ͻ10 mSv) to the patient. These data suggest that hybrid positron emission tomography/ computed tomography imaging of the heart is a feasible, accurate method to assess coronary artery disease noninvasively in a symptomatic, moderate-risk patient population.
Conclusion: Cardiac hybrid PET/CT imaging allows accurate noninvasive detection of coronary artery disease in a symptomatic population. The method is feasible and can be performed routinely with Ͻ10 mSv in most patients. 51
First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
Summary: Anticoagulants for percutaneous coronary intervention (PCI) are limited by unpredictable pharmacodynamics and/or lack of active reversibility. The REG1 system is an oligonucleotide RNA aptamer pair comprising the direct rapid-onset factor IXa inhibitor RB006 and its active dose-dependent control agent RB007. REG1 offers effective, predictable, and reversible anticoagulation. We assessed whether anticoagulation through factor IXa inhibition with RB006 could support low-to moderate-risk PCI. This phase IIa study enrolled 26 patients undergoing elective PCI. In a roll-in group, 2 patients received REG1 and glycoprotein IIb/IIIa inhibitors. Then, 24 patients were randomized 5:1 to REG1 (nϭ20) or unfractionated heparin (nϭ4). REG1 patients received RB006 (1 mg/kg) after arterial access. In the first 10 REG1 patients, RB007 was dosed to partially reverse RB006ϫ50% after PCI and to completely reverse RB006 at 4 hours. In the subsequent 10 REG1 patients, RB007 was dosed once to completely reverse RB006 immediately after PCI. All PCI procedures were successful without angiographic procedural thrombotic events or catheter thrombus, and bleeding was infrequent. Baseline plasma and whole-blood activated partial thromboplastin time increased by 2.5-and 1.8-fold 5 minutes after RB006 and remained stable. Activated clotting time was Ն225 seconds in all cases and remained stable with RB006 but trended upward with unfractionated heparin. Partial RB007 reversal reduced RB006 activity by 51Ϯ14% to 68Ϯ15%. Complete reversal reduced RB006 activity by 93Ϯ11% to 103Ϯ13%, depending on the assay. Anticoagulation through factor IXa inhibition with RB006, followed by active reversal with RB007, was feasible and may favorably shift the balance of safety and efficacy during PCI.
Conclusions: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation. 52
Intra-Arrest Transnasal Evaporative Cooling: A Randomized, Prehospital, Multicenter Study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness)
Summary: Therapeutic hypothermia has been shown to benefit survival in survivors of ventricular fibrillation or ventricular tachycardia, even when cooling is initiated with substantial delays in a hospital setting. Current guidelines from the American Heart Association and the International Liaison Committee on Resuscitation recommend cooling all such patients, and the use of cooling is becoming the standard of care in this setting. Many animal studies have shown significant added benefit when cooling is initiated earlier, with maximal benefit achieved when cooling is initiated during the arrest. Intra-arrest cooling has been shown to ease the resuscitation effort, increase resuscitation rates, and improve subsequent myocardial function. To date, intra-arrest cooling has not been studied in randomized human studies, largely because of the absence of methods suitable for use in the field. We have studied a new method of transnasal evaporative cooling that allows cooling to be initiated within minutes of the arrest and that has been shown to cool the brain before circulation is reestablished. The device previously has been shown to be safe for use in humans in an emergency room setting. In a randomized field study, we have shown that this method of cooling can be performed safely during an arrest without derailing the resuscitation effort and that it is relatively easy to implement. Furthermore, we have shown that target tympanic and core temperatures are achieved several hours earlier than with standard hospitalbased cooling. Although outcomes are reported, larger studies will be required to determine the extent of the added outcome benefit over hospital-based cooling alone.
Conclusions: Prehospital intra-arrest transnasal cooling is safe and feasible and is associated with a significant improvement in the time intervals required to cool patients. 53
Induction of Therapeutic Hypothermia by Paramedics After Resuscitation From Out-of-Hospital Ventricular Fibrillation Cardiac Arrest: A Randomized Controlled Trial
Summary: The induction of therapeutic hypothermia after resuscitation from out-of-hospital ventricular fibrillation cardiac arrest is recommended for the treatment of neurological injury by the American Heart Association; however, the optimal timing of this intervention is uncertain. Laboratory studies suggest that earlier cooling may improve neurological outcomes. This study reports the results of a randomized controlled trial in 234 patients comparing paramedic cooling after return of a circulation by use of a rapid infusion of large-volume, ice-cold intravenous fluid with cooling after hospital arrival. Paramedic cooling decreased core temperature by 0.8°C compared with patients allocated to hospital cooling, but the outcomes at hospital discharge were similar in both groups. Further research into cooling during cardiopulmonary resuscitation should be undertaken.
Conclusions:
In adults who have been resuscitated from out-ofhospital cardiac arrest with an initial cardiac rhythm of ventricular fibrillation, paramedic cooling with a rapid infusion of large-volume, ice-cold intravenous fluid decreased core temperature at hospital arrival but was not shown to improve outcome at hospital discharge compared with cooling commenced in the hospital. 54
Birth Weight Is a Significant Risk Factor for Incident Atrial Fibrillation
Summary: Although birth weight has been associated with the risk of coronary disease and stroke, few if any studies have assessed the influence of birth weight on the risk of developing atrial fibrillation.
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We prospectively followed up 27 982 women who were Ͼ45 years of age and free of cardiovascular disease and atrial fibrillation at baseline. Birth weight was categorized into 5 different categories: Ͻ2.5, 2.5 to 3.2, 3.2 to 3.9, 3.9 to 4.5, and Ͼ4.5 kg. We found that higher birth weight was associated with an increased risk of atrial fibrillation during adulthood. The 2 highest categories were associated with a 70% and 71% increased risk after multivariable adjustment. Further adjustment for adult height and maximum body weight in young adulthood substantially attenuated these findings. Our results therefore demonstrate that birth weight is significantly associated with incident atrial fibrillation among women. We believe that our findings also suggest that early life determinants may play an important role in the pathogenesis of atrial fibrillation. Most of this effect seems to be mediated through height and cumulative lifetime exposure to elevated body mass. In this context, the increasing prevalence of newborns with an elevated birth weight over the last decades might provide one explanation for the increasing AF burden in Western societies.
Conclusions: Birth weight is significantly associated with incident atrial fibrillation among women, suggesting that early life determinants may play an important role in the pathogenesis of atrial fibrillation. 55
Vascular Reactivity and Flow Characteristics of Radial Artery and Long Saphenous Vein Coronary Bypass Grafts: A 5-Year Follow-Up
Summary: We have demonstrated, in a randomized clinical trial (the Radial Artery versus Saphenous Vein Patency [RSVP] trial), that radial artery (RA) aortocoronary bypass grafts anastomosed to a branch of the circumflex coronary artery have significantly better patency rates than saphenous vein (SV) grafts at 5 years. The reasons for this are relatively unexplored. In a substudy from this trial, we now report preserved vascular function in RA but not SV grafts 5 years after surgery, which may at least in part explain the patency results of the RSVP trial. The primary finding from this study is that RA aortocoronary bypass grafts are living conduits at 5 years, with the ability to autoregulate their diameter in response to changes in myocardial flow physiology, similar to that which has been observed and reported for the pedicle left internal mammary artery graft. The SV grafts, devoid of their vascular autoregulatory function, are merely passive conduits at 5 years. This may result in the SV grafts being subjected to extreme flow stresses, resulting in repeated cycles of injury and repair, and this may be one of the mechanisms that may contribute to the less favorable patency rate in SV compared with RA aortocoronary conduits in the longer term. Our clinical trial results, with the use of excellent surgical technique, support the use of the RA in aortocoronary bypass graft surgery, which we hope will result in the more widespread and acceptable use of the RA as an aortocoronary conduit.
Conclusions: Five years after surgery, RA coronary bypass conduits grafted to a single coronary territory demonstrated preserved flowmediated vasodilatation, whereas SV grafts did not. Our results may provide insight into the more favorable patency of RA grafts over SV grafts. 56
Ten-Year Follow-Up Survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A Randomized Controlled Clinical Trial of 3 Therapeutic Strategies for Multivessel Coronary Artery Disease
Summary: Patients who are symptomatic because of coronary artery disease can be managed with medical therapy (MT), percutaneous coronary interventions (PCI), bypass surgery (CABG), or a combination of these strategies. It is unknown which treatment approach is best for specific patient subgroups. Here, we report 10-year follow-up of the second Medicine, Angioplasty, or Surgery Study (MASS II), a study that evaluated MT alone, PCI, or CABG among stable coronary patients with multivessel disease. No differences were observed in overall mortality in patients treated with CABG, PCI, or MT. Nevertheless, compared with CABG, MT was associated with a significantly higher incidence of cardiac death, subsequent myocardial infarction, and additional revascularization. Overall, compared with CABG, MT was associated with a 2.29-fold increased risk of combined events. Event rates for PCI patients were intermediate between MT and CABG. Indeed, by finding the lowest rate of further interventions in the CABG group, our results support a strategy of revascularization, and in particular CABG, in addition to MT for selected stable coronary patients with multivessel disease.
Conclusions: Compared with CABG, MT was associated with a significantly higher incidence of subsequent myocardial infarction, a higher rate of additional revascularization, a higher incidence of cardiac death, and consequently a 2.29-fold increased risk of combined events. PCI was associated with an increased need for further revascularization, a higher incidence of myocardial infarction, and a 1.46-fold increased risk of combined events compared with CABG. Additionally, CABG was better than MT at eliminating anginal symptoms. 57
Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis
Summary: Endothelial dysfunction is considered critical in the initiation, progression, and complications of coronary artery disease and is independently associated with cardiovascular events. It is a reversible process that represents the functional expression of an individual's overall cardiovascular risk factor burden, and many therapies that restore endothelial function also decrease cardiovascular events. Coronary endothelial function is regulated by the balance of endothelium-derived vasodilator and vasoconstrictor factors such as endothelin-1. This study provides evidence that longterm ETA receptor antagonist administration improves coronary microvascular endothelial function in humans and supports a role for endogenous endothelin in the mechanism and potentially the treatment of coronary endothelial function in humans.
Conclusions:
This study demonstrates that 6-month treatment with atrasentan improves coronary microvascular endothelial function and supports the role of the endogenous endothelin system in the regulation of endothelial function in early atherosclerosis in humans. 58
Effect of Cardiac Resynchronization Therapy on Reverse Remodeling and Relation to Outcome: Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy
Summary: Cardiac resynchronization therapy has been shown to reduce the risk of death or heart failure in patients with class III or IV heart failure. The Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy (MADIT-CRT) study extended these results to patients with class I and II heart failure. In this echocardiographic substudy of MADIT-CRT, we observed substantial improvement in cardiac size and function in patients who received combined therapy with cardiac resynchronization and an implantable cardioverter defibrillator versus those receiving implantable cardioverter defibrillator therapy only. We observed reductions in end-diastolic volume, end-systolic volume, and left atrial volume and improvement in left ventricular ejection fraction and right ventricular fractional area change. These findings were concordant with the improvement in outcomes, and outcomes after 1 year were directly related to the extent of improvement in ventricular size and function between baseline and 1 year. These data provide a direct link between the improvement in cardiac size and function with CRT and improvement in outcomes.
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Conclusions: CRT resulted in significant improvement in cardiac size and performance compared with an ICD-only strategy in patients with mildly symptomatic heart failure. Improvement in these measures accounted for the outcomes benefit. 59
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Summary: Among patients with acute coronary syndromes, any degree of impairment of renal function is associated with a worse prognosis but also an increased bleeding risk, which may alter the risk-benefit ratio with antiplatelet therapies. The Platelet Inhibition and Patient Outcomes (PLATO) trial investigated the effects of ticagrelor compared with clopidogrel in a broad population of patients with non-ST-segment elevation acute coronary syndromes, regardless of the intended management strategy. Patients with chronic kidney disease, defined as a baseline creatinine clearance Ͻ60 mL/min, constituted 21% of those with baseline creatinine measurements (15 202 ). The numeric absolute (and relative) risk reductions of the primary composite end point and total mortality by ticagrelor versus clopidogrel were 4.7% (23%) and 4.0% (28%) in patients with chronic kidney disease and 1% (10%) and 0.5% (11%) in patients with normal renal function. The incidence of major bleeding did not differ significantly between the ticagrelor and clopidogrel groups in patients with normal renal function or in patients with chronic kidney disease. Thus, ticagrelor is a more effective antiplatelet agent than clopidogrel in acute coronary syndrome patients regardless of renal function, and the benefits are larger in those with poor renal function without any need for dose reduction to prevent major bleeding. Given the high prevalence of renal dysfunction among patients with atherosclerotic disease and the associated elevated risk of ischemic and bleeding complications, ticagrelor provides an important opportunity to substantially improve outcome in patients with acute coronary syndromes and impaired renal function.
Conclusions:
In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more nonprocedure-related bleeding. 60
Incidence, Mechanisms, Predictors, and Clinical Impact of Acute and Late Stent Malapposition After Primary Intervention in Patients With Acute Myocardial Infarction: An Intravascular Ultrasound Substudy of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Summary: The prognosis for patients with acute myocardial infarction has been improved by primary percutaneous coronary intervention, especially the implantation of bare-metal stents (BMS) or drug-eluting stents. However, there is an increased frequency of late stent malapposition after drug-eluting stent implantation. In the prospective, multicenter Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, patients with ST-elevation myocardial infarction within 12 hours of symptom onset were randomized 3:1 to TAXUS EXPRESS paclitaxeleluting stents (PES) versus EXPRESS BMS. The present intravascular ultrasound substudy included 241 patients with 263 native coronary lesions (201 PES, 62 BMS) with poststenting and 13-month follow-up intravascular ultrasound imaging. Postintervention acute stent malapposition occurred in 34.3% PES-and 40.3% BMS-treated lesions. The reason for resolved acute stent malapposition was negative remodeling with larger acute stent malapposition areas (Ͼ1.2 mm 2 ) separating persistent from resolved acute stent malapposition. At follow-up, a higher frequency of late stent malapposition was detected in PES-treated lesions (46.8%) mainly because of more late acquired stent malappositions (30.8%) compared with BMStreated lesions. Late acquired stent malapposition was attributable to plaque/thrombus resolution in both BMS and PES and to positive remodeling in PES; the largest areas of late stent malapposition either persisted from implantation or were seen in lesions with positive remodeling. However, the number of events related to stent malapposition was small (with no deaths or stent thrombosis), and follow-up was limited to only 1 year; therefore, longer follow-up is required to determine the relationship of long-term major adverse cardiac events (and especially very late stent thrombosis) and late stent malapposition.
Conclusions: The incidence of acute stent malapposition was similar in PES-and BMS-treated lesions, but late acquired stent malapposition was more common in PES-treated lesions. The reason for resolved acute stent malapposition was negative remodeling, with larger acute stent malapposition areas separating persistent from resolved acute stent malapposition. Late acquired stent malapposition was due mainly to positive remodeling and plaque/thrombus resolution. 61
Multicenter Cluster-Randomized Trial of a Multifactorial Intervention to Improve Antihypertensive Medication Adherence and Blood Pressure Control Among Patients at High Cardiovascular Risk (The COM99 Study)
Summary: Nonadherence to antihypertensive medication is prevalent in clinical practice; however, the prevalence of nonadherence to antihypertensive medication might not be as high in Western societies as previously thought. In this study, we found high rates of adherence in both the control and the intervention group. Although electronic measurement of adherence may have introduced a Hawthorne effect in our study (and thereby promoted adherence in both groups), recent studies using other methods of measuring adherence have also found high rates of adherence to antihypertensive medication. This multifactorial adherence intervention had 3 main components 1 : the counting of pills during physician visits, 2 designation of a family member to support adherence behavior, and 3 provision of an information sheet to patients that included information on each antihypertensive medication dose and frequency, potential medication side effects, and how the medication was to be taken. Patients in the intervention group had small but significant improvements in both adherence and blood pressure control. No effects were found on cardiovascular morbidity and mortality, but the study was not sufficiently powered for these outcomes. Although the intervention was designed to be feasible in clinical practice (ie, simple and inexpensive to implement), it did increase the average length of an office visit by Ϸ7 minutes. Although this amount of time might be prohibitive in some busy clinical settings, it did appear sufficient to improve patient adherence, which is often considered an intransigent problem. Perhaps future interventions can also involve other clinical professionals who can provide additional time and focus on patient medication adherence.
Conclusions:
A multifactorial intervention to improve adherence to antihypertensive medication was effective in improving both adherence and blood pressure control, but it did not appear to improve long-term cardiovascular events. 62
Long-Term Recording of Cardiac Arrhythmias With an Implantable Cardiac Monitor in Patients With Reduced Ejection Fraction After Acute Myocardial Infarction: The Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) Study
Summary: Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) reports on long-term cardiac
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arrhythmias recorded by an implantable cardiac monitor in patients with left ventricular Յ40% after myocardial infarction. Clinically significant bradyarrhythmias and tachyarrhythmias were documented in a substantial proportion of patients, most of them asymptomatic. A large number of the documented arrhythmias would result in device therapy according to the current guidelines. The most significant arrhythmia was intermittent high-degree atrioventricular block, which was associated with a very high risk of cardiac death. However, the study was observational, and whether the use of implantable cardiac monitors in this population could improve clinical outcome should be tested in larger randomized trials.
Conclusions: This is the first study to report on long-term cardiac arrhythmias recorded by an implantable loop recorder in patients with left ventricular ejection fraction Յ40% after myocardial infarction. Clinically significant bradyarrhythmias and tachyarrhythmias were documented in a substantial proportion of patients with depressed left ventricular ejection fraction after acute myocardial infarction. Intermittent high-degree atrioventricular block was associated with a very high risk of cardiac death. 63
Complication Rates Associated With Pacemaker or Implantable Cardioverter-Defibrillator Generator Replacements and Upgrade Procedures: Results From the REPLACE Registry
Summary: Cardiac implantable electronic device use is increasing worldwide. Improvements in medical therapy will result in many patients requiring subsequent procedures for generator replacement or "upgrades" to multilead systems. Although data from retrospective series have been available, REPLACE is the first prospective multicenter trial to examine complications related to generator replacement. The 2 patient populations studied included patients who needed only a generator replacement and those who required a lead addition or revision for advanced therapy. This study examined a broad range of major and minor complications. Major complications with planned generator replacements alone were modest; however, when a transvenous lead addition or revision was combined with a generator replacement, the risk was markedly higher, especially for left ventricular leads. Our results support the use and development of devices with long battery life to minimize the lifetime surgical risk for a patient. The choice of device for each patient must be carefully considered. Mitigation of lead-related risks is also important. Using the fewest leads necessary for the clinical need of the patient is critical. The risk associated with upgrade procedures is concerning and favors performing indicated complex procedures before the development of advanced end-stage medical and cardiac disease, situations in which the risk may be prohibitive. Finally, our results provide insight into procedural outcomes for the next phase of life for patients who receive cardiac implantable electronic devices and a more robust analysis that can be used to establish a benchmark for comparative performance in this time of healthcare reform.
Conclusions: Pacemaker and implantable cardioverter-defibrillator generator replacements are associated with a notable complication risk, particularly those with lead additions. These data support careful decision making before device replacement, when managing device advisories, and when considering upgrades to more complex systems. 64
Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
Summary: Cardiac energy impairment is a consistent feature of hypertrophic cardiomyopathy and precedes the development of hypertrophy. We hypothesized that this energy deficiency plays a key role in the pathophysiology of exercise limitation via impairment of the highly energy-dependent process of left ventricular active relaxation on exercise. To test this hypothesis, we assessed whether the metabolic modulator perhexiline augmented myocardial energetics in hypertrophic cardiomyopathy and whether this translated into improved physiological and clinical outcomes in a randomized, double-blind, placebo-controlled study. In accordance with previous studies, the hypertrophic cardiomyopathy patients in the present study, who were symptomatic but manifested no left ventricular outflow tract obstruction, had a significantly decreased myocardial energy charge as assessed by 31P magnetic resonance spectroscopy; this was accompanied by a paradoxical dynamic slowing of myocardial relaxation during exercise. Perhexiline improved myocardial energetics, normalized the impairment of dynamic myocardial relaxation, and improved both patient symptoms and exercise capacity.
The results of the present study support the hypothesis that energy deficiency contributes to the pathophysiology of exercise limitation in hypertrophic cardiomyopathy and that augmenting myocardial energetics through metabolic modulation may be a novel and potentially effective therapy for the management of symptomatic hypertrophic cardiomyopathy in patients without left ventricular outflow tract obstruction, although this requires confirmation in a larger study. The therapeutic potential is especially important in this group of patients in whom treatment options are limited.
Conclusions:
In symptomatic hypertrophic cardiomyopathy, perhexiline, a modulator of substrate metabolism, ameliorates cardiac energetic impairment, corrects diastolic dysfunction, and increases exercise capacity. This study supports the hypothesis that energy deficiency contributes to the pathophysiology and provides a rationale for further consideration of metabolic therapies in hypertrophic cardiomyopathy. 65
Health Status After Treatment for Coronary Artery Disease and Type 2 Diabetes Mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial
Summary: Several treatment options exist for patients with the combination of stable ischemic heart disease and type 2 diabetes mellitus. With a 2-by-2 factorial design, the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) clinical trial compared insulin sensitization versus insulin provision to control hyperglycemia and prompt revascularization with intensive medical therapy versus intensive medical therapy to treat cardiac ischemia and found no mortality differences between these strategies after 5 years of follow-up. Therefore, patient-assessed health status could be a key factor in differentiating treatments. This analysis of the BARI 2D trial illustrates that rigorous coordinated care of diabetes mellitus and cardiac risk factors results in clinically meaningful and statistically significant improvement in health status. Over 4 years of follow-up, physical function, Energy, Health Distress, and Self-Rated Health were similar for patients treated with a strategy focused on insulin sensitization versus insulin provision, indicating that either glycemic approach is appropriate relative to health status outcomes. The addition of prompt revascularization to intensive medical therapy resulted in small but statistically significant benefits in physical function and Self-Rated Health and marginally significant benefits in Energy. The effect of prompt revascularization on physical function was greater among patients selected for coronary artery bypass grafting than among those selected for percutaneous coronary intervention, whereas the benefits of prompt revascularization on Self-Rated Health and Energy were evident irrespective of the method of revascularization. Thus, patient-perceived health status among those with type 2 diabetes mellitus and stable ischemic heart disease appears to be, on average, slightly better when a strategy of prompt revascularization is undertaken, although marked variability among patients was observed.
Conclusions: Prompt coronary revascularization was associated with small yet statistically significant improvements in health status compared with initial medical therapy among patients with diabetes mellitus and stable ischemic heart disease. 66
Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis
Summary: Lasofoxifene is a selective estrogen receptor modulator with high affinity and selectivity for estrogen receptors. The Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial in 8556 postmenopausal women with osteoporosis previously reported that treatment with lasofoxifene 0.5 mg/d for 5 years reduced the risk of fractures, estrogen receptor-positive breast cancer, major coronary heart disease (CHD) events, and stroke but increased the risk of venous thromboembolic events. Here, we provide comprehensive cardiovascular end point data, including the component events making up the composite end point of major CHD events, and evaluate whether the effects of lasofoxifene 0. . Although both hazard ratios were Ͻ1.0, no significant effect of lasofoxifene at 0.5 mg/d was demonstrated for coronary death or nonfatal myocardial infarction. The effectiveness of lasofoxifene 0.5 mg/d in reducing CHD events was similar across strata of major cardiovascular risk factors, including history of CHD and 10-year absolute probability of developing CHD. Lasofoxifene 0.5 mg/d appears to have a favorable benefit-to-risk profile for cardiovascular events. Randomized trials of lasofoxifene in postmenopausal women at increased CVD risk are warranted.
Conclusions:
In postmenopausal women with osteoporosis, lasofoxifene 0.5 mg/d for 5 years reduced the risk of CHD events, regardless of the presence or absence of risk factors for cardiovascular disease. The significant reduction in risk of CHD events with lasofoxifene 0.5 mg/d was due primarily to lower risks of coronary revascularization procedures, hospitalization for unstable angina, and diagnosis of new ischemic heart disease. 67
Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease
Summary: Nonsteroidal anti-inflammatory drugs have been shown to increase the risk for cardiovascular events. In patients with coronary artery disease, current guidelines therefore suggest avoiding such drugs and recommend acetaminophen as the first-line analgesic of choice instead. However, the results of the present prospective study provide the first evidence of a blood pressure elevation in these patients, thus questioning the assumption of the cardiovascular safety of acetaminophen. In view of the established continuous incremental risk of cardiovascular and cerebrovascular disease in relation to blood pressure, an elevation associated with the use of acetaminophen could further increase the risk of myocardial infarction and stroke in patients at high cardiovascular risk or, in particular, in those with established cardiovascular disease. Because the use of acetaminophen is frequent, the blood pressure increase caused by this drug is a potential public health concern. Unless the cardiovascular safety of acetaminophen has been cleared in randomized controlled clinical trials specifically addressing the safety of this agent, the use of acetaminophen should be evaluated as rigorously as all traditional anti-inflammatory drugs, particularly in patients at increased cardiovascular risk.
Conclusions:
This study demonstrates for the first time that acetaminophen induces a significant increase in ambulatory blood pressure in patients with coronary artery disease. Thus, the use of acetaminophen should be evaluated as rigorously as traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, particularly in patients at increased cardiovascular risk. 68
Ticagrelor Versus Clopidogrel in Patients With
ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis
Summary: Ticagrelor, a reversible oral P2Y12-receptor antagonist, provides faster, greater, and more consistent platelet inhibition than clopidogrel. We compared ticagrelor with clopidogrel within the subset of 7544 patients with ST-segment elevation acute myocardial infarction and planned percutaneous coronary intervention from the Platelet Inhibition and Patient Outcomes (PLATO) randomized, double-blind trial. Patients were allocated to ticagrelor 180-mg loading dose followed by 90 mg twice daily or to clopidogrel 300-mg loading dose (with provision for 300 mg clopidogrel at percutaneous coronary intervention) followed by 75 mg daily for 6 to 12 months plus aspirin. Dyspnea was more frequent with ticagrelor than with clopidogrel but rarely required drug discontinuation (0.5% versus 0.1%; Pϭ0.0004). Given the mortality reduction without increased risk of major bleeding, ticagrelor is an attractive alternative to clopidogrel for patients with ST-segment elevation myocardial infarction and planned percutaneous coronary intervention.
Conclusion:
In patients with STE-ACS and planned primary percutaneous coronary intervention, the effects of ticagrelor were consistent with those observed in the overall PLATO trial. 69
What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes? Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial
Summary: Although aggressive blood pressure (BP) control has been advocated in patients with diabetes and more recently in those with acute coronary syndromes, recent trials and observational studies in stable diabetic patients have challenged this concept by finding that more intensive BP lowering was not superior to standard BP lowering. We found in a population of 4162 post-acute coronary syndrome patients that a J-or U-shaped curve existed between BP and the risk of future cardiovascular events, with the lowest event rates in the BP range of approximately 130 to 140/80 to 90 mm Hg. Thus, our findings are consistent with recent studies in stable patients but extend the observation to high-risk post-acute coronary syndrome patients. As such, this study helps provide evidence that clinicians treating hypertension should aim for a systolic BP Ͻ140 mm Hg but not Ͻ110 mm Hg.
Conclusions: After acute coronary syndrome, a J-or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130
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to 140 mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg, which suggests that too low of a pressure (especially Ͻ110/70 mm Hg) may be dangerous. 70
OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction
Summary: The OMEGA study demonstrates that current guidelineadjusted therapy of acute myocardial infarction results in a low rate of mortality, nonfatal reinfarction, or stroke during 1 year of follow-up. This low rate of major clinical events appears to be difficult to improve further with additional therapeutic regimen. In particular, an additional beneficial effect of omega-3 fatty acids on mortality and recurrent nonfatal myocardial infarction during follow-up of patients surviving acute myocardial infarction remains to be proven and is not supported by the OMEGA study.
Conclusions: Guideline-adjusted treatment of acute myocardial infarction results in a low rate of sudden cardiac death and other clinical events within 1 year of follow-up, which could not be shown to be further reduced by the application of omega-3 fatty acids. 71
Cryoablation Versus Radiofrequency Energy for the Ablation of Atrioventricular Nodal Reentrant Tachycardia (the CYRANO Study): Results From a Large Multicenter Prospective Randomized Trial
Summary: This large prospective randomized study including 509 patients compares the short-and long-term efficacy and complications of radiofrequency catheter ablation (RFCA) versus cryoablation of the slow atrioventricular (AV) pathway in AV nodal reentrant tachycardia (AVNRT). Significantly more patients in the cryoablation than in the RFCA group reached the combined primary end point of immediate ablation failure, permanent AV block, and AVNRT recurrence (12.6% versus 6.3%; Pϭ0.018). The difference in primary end point was driven almost exclusively by the significantly higher rate of AVNRT recurrence after cryoablation (9.4% versus 4.4%; Pϭ0.029), although short-term success was equally high in both groups (96.8% for cryoablation versus 98.4% for RFCA). Occurrence of permanent AV block (0% for cryoablation versus 0.4% for RFCA) was rare. Cryoablation procedures lasted significantly longer than RFCA, and significantly more devicerelated problems occurred with cryoablation than with RFCA. Pain perception was lower in the cryoablation group (PϽ0.001). In summary, cryoablation in patients with AVNRT is associated with a comparably high immediate success rate as RF. However, the significantly higher recurrence rate after cryoablation is probably the main limitation of using this energy form for AVNRT ablation, especially because the potential safety benefit of cryoenergy seems negligible. The advantage of less pain perception with cryoablation is counterbalanced by longer procedure times and frequent device functionality failure.
Conclusions: Cryoablation for AVNRT is as effective as RFCA over the short term but is associated with a higher recurrence rate at the 6-month follow-up. The risk of permanent AV block does not differ significantly between cryoablation and RFCA. The potential benefits of cryoenergy relative to ablation safety and pain perception are counterbalanced by longer procedure times, more device problems, and a high recurrence rate. 72
Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation
Summary: This report compares the novel anticoagulant dabigatran with the current standard, warfarin, in vitamin K antagonist-naive and -experienced populations of patients with atrial fibrillation who are at risk of stroke. It was believed that patients who were vitamin K antagonist experienced were likely to do better than patients who are new to anticoagulation because they have demonstrated the ability to comply with an anticoagulation regimen, they have a personalized dose of warfarin that achieves a therapeutic international normalized ratio value, and they have passed the "vitamin K antagonist stress test," thereby reducing the chance of uncovering major sources of bleeding. This report found that dabigatran, the novel direct thrombin inhibitor, was better than the comparator warfarin for both vitamin K antagonist-naive and -experienced patients and therefore could be used clinically in both cases.
Conclusions: Previous vitamin K antagonist exposure does not influence the benefits of dabigatran at either dose compared with warfarin. 73
Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes
Summary: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified. Forty-five patients successfully received a second-generation bioresorbable everolimus drug-eluting vascular scaffold. One patient had postprocedural release of myocardial enzyme without Q-wave occurrence; 1 patient was treated 1 month later with a metallic drug-eluting stent. At the 6-month follow-up, quantitative coronary angiography disclosed 1 edge restenosis (in-segment binary restenosis, 2.4%). The backscattering of the polymeric struts did not decrease over time; the scaffold area was reduced by only 2.0% with intravascular ultrasound, and no change was noted with optical coherence tomography. The late lumen loss amounted to 0.19Ϯ0.18 mm with a limited relative decrease in minimal luminal area of 5.4% on intravascular ultrasound. Optical coherence tomography showed at follow-up that 96.8% of the struts were covered and that malapposition was detected at follow-up in only 3 scaffolds. Mean neointimal growth measured by optical coherence tomography between and on top of the polymeric struts equaled 1.25 mm 2 , or 16.6% of the scaffold area. A modified manufacturing process of the polymer and geometric changes in the polymeric platform have substantially improved the medium-term performance of the new generation of drug-eluting scaffold, making it comparable to that of current drug-eluting stents. The results constitute proof of concept that this device can adequately revascularize coronary vessels and prevent restenosis.
Conclusion: Modified manufacturing process of the polymer and geometric changes in the polymeric platform have substantially improved the medium-term performance of this new generation of drug-eluting scaffold to become comparable to those of current drug eluting stents. 74 rosis. Furthermore, sPLA 2 levels increase after percutaneous coronary intervention (PCI), with higher levels being associated with worse long-term outcome. Inhibitors of sPLA 2 have been shown to reduce experimental ischemia/reperfusion injury. The possibility that sPLA 2 inhibition could reduce myocardial injury after elective percutaneous coronary intervention was thus intriguing. In the sPLA 2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) randomized placebo controlled trial, we tested the hypothesis that varespladib, a selective inhibitor of the sPLA 2 -IIa, sPLA 2 -V, and sPLA 2 -X isoforms, would reduce the occurrence of elevation of troponin I or creatine kinase-MB above the upper limit of normal within 24 hours after percutaneous coronary intervention when administered at a dose of 500 mg twice daily from 3 to 5 days before and up to 5 days after the procedure. Treatment with varespladib profoundly inhibited sPLA 2 but did not reduce postprocedural rise in biomarkers. Furthermore, elevation of creatine kinase-MB to twice the upper limit of normal occurred significantly more frequently in the varespladib group than in the placebo group. It is possible that this was a chance finding. However, different sPLA 2 inhibitors may potentially have different effects on platelet activation and arachidonic acid/prostaglandin pathways. Varespladib is not known to interact with these pathways adversely. However, as development of this agent moves into phase III acute coronary syndrome trials, our data suggest that further surveillance is warranted to ensure not only that the agent can stabilize the chronic inflammatory milieu of the atherosclerotic vascular wall but also that it is safe and efficacious during acute myocardial ischemia.
Conclusions: Inhibition of sPLA 2 by varespladib administered for 3 to 5 days before the procedure does not reduce periprocedural myonecrosis associated with elective percutaneous coronary intervention. 75
Economic Evaluation of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease
Summary: The Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) study demonstrated that performing percutaneous coronary intervention guided by fractional flow reserve measurement in patients with multivessel coronary artery disease leads to improved outcomes at 1 year compared with the traditional approach of using angiography alone to guide percutaneous coronary intervention. In this economic evaluation of the FAME study, we find that a fractional flow reserve-guided strategy not only improves outcomes but also saves money at 1 year. This finding provides further support for the routine measurement of fractional flow reserve in patients with multivessel coronary artery disease undergoing percutaneous coronary intervention.
Conclusion: Economic evaluation of the FAME study reveals that fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel coronary disease is one of those rare situations in which a new technology not only improves outcomes but also saves resources. 76
Primary Results From the SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) Trial: A Randomized Trial Comparing Empirical, Echocardiography-Guided, and Algorithmic Atrioventricular Delay Programming in Cardiac Resynchronization Therapy
Summary: The clinical benefit of cardiac resynchronization therapy for patients with moderate to severe symptomatic heart failure, severe left ventricular systolic dysfunction, and intraventricular conduction delay is firmly established. Nonetheless, a significant number of patients derive limited benefit from cardiac resynchronization therapy. One possibility is that systematic optimization of the programmed atrioventricular (AV) delay might improve overall outcomes. A variety of methods are used clinically for programming the AV delay, with no current consensus on the best practice. The SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) delay trial prospectively randomized patients to a fixed empirical AV delay (120 milliseconds), echocardiographically optimized AV delay, or AV delay optimized with SmartDelay, an empirically derived electrogram-based algorithm. A total of 980 patients were randomized and followed up for 6 months. At the end of the trial, there was no difference in the primary end point, left ventricular end-systolic volume, or any of the secondary end points: left ventricular end-diastolic volume, ejection fraction, New York Heart Association class, quality of life, and 6-minute walk distance. The routine use of echocardiographic optimization and algorithmbased AV interval optimization is not clinically warranted. However, these data do not exclude possible utility in selected patients who do not respond to cardiac resynchronization therapy.
Conclusions: Neither SmartDelay nor echocardiography was superior to a fixed AV delay of 120 milliseconds. The routine use of AV optimization techniques assessed in this trial is not warranted. However, these data do not exclude possible utility in selected patients who do not respond to cardiac resynchronization therapy. 77
Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial
Summary: Coronary artery bypass grafting (CABG) is an effective treatment for ischemic heart disease, but its long-term results are compromised by the development of saphenous vein graft (SVG) disease. After surgery, a platelet-mediated thickening of the SVG wall occurs, with smooth muscle cell proliferation and extracellular matrix protein synthesis. This process, termed intimal hyperplasia, forms a template for the development of SVG atherosclerosis and eventual occlusion. Clopidogrel has been shown to inhibit intimal hyperplasia in animal studies and therefore may reduce SVG intimal hyperplasia after coronary artery bypass grafting. In the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study, we conducted a double-blind, placebo-controlled trial to evaluate whether the addition of clopidogrel to aspirin inhibits the development of SVG disease. A total of 113 patients undergoing coronary artery bypass grafting with SVGs were randomized to receive either aspirin 162 mg plus clopidogrel 75 mg daily or aspirin 162 mg plus placebo daily for 1 year, followed by SVG intravascular ultrasound and coronary angiography. The primary outcome, SVG intimal area at 1 year, did not differ significantly between the 2 groups (4.1Ϯ2.0 versus 4.5Ϯ2.1 mm 2 , aspirin-clopidogrel versus aspirin-placebo, Pϭ0.44). Graft patency and freedom from major adverse cardiovascular events also did not significantly differ between the 2 groups. In summary, CASCADE indicated that compared with aspirin monotherapy, the combination of aspirin plus clopidogrel did not significantly reduce SVG intimal hyperplasia 1 year after coronary artery bypass grafting. Newer antiplatelet agents with purported advantages over clopidogrel may constitute important areas for future research to target the inhibition of SVG disease after CABG.
Conclusions: Compared with aspirin monotherapy, the combination of aspirin plus clopidogrel did not significantly reduce the process of SVG intimal hyperplasia 1 year after coronary artery bypass grafting. 78
Intracoronary Versus Intravenous Administration of Abciximab in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention With Thrombus Aspiration: The Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) Trial
Summary: Administration of the glycoprotein IIb/IIIa inhibitor abciximab is an effective adjunctive antiplatelet strategy during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Experimental studies have reported that higher local concentrations of abciximab exert additional effects, including disaggregation of newly formed thrombus, and can be achieved by intracoronary administration. Recently, small-scale studies have suggested beneficial clinical effects of intracoronary over intravenous administration. In the present Comparison of Intracoronary versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial, 534 ST-segment elevation myocardial infarction patients were randomized within 12 hours of symptom onset to either an intracoronary or an intravenous bolus of abciximab during primary percutaneous coronary intervention with thrombus aspiration. Patients were pretreated with aspirin, heparin, and highdose clopidogrel. Intracoronary administration of abciximab compared with intravenous administration did not improve the rate of successful myocardial reperfusion as assessed by ST-segment resolution. In contrast, intracoronary administration was associated with a significantly higher rate of successful myocardial reperfusion as assessed by myocardial blush grade and a smaller enzymatic infarct size. In addition, bleeding complications occurred at similar frequencies between both treatment groups. Although intracoronary administration did not improve the primary end point of ST-segment resolution, the beneficial effects on secondary end points may translate into improved clinical outcome. Larger randomized multicenter trials are required to investigate whether intracoronary administration of abciximab reduces major adverse cardiac events.
Conclusions:
In ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with thrombus aspiration, intracoronary administration of abciximab compared with intravenous administration does not improve myocardial reperfusion as assessed by ST-segment resolution. However, intracoronary administration is associated with improved myocardial reperfusion as assessed by myocardial blush grade and a smaller enzymatic infarct size. 79 
